Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220548 | 0.88 | ALDH1A1 (0.38) | GLATSHRALDH1A1P2RX7MAOB | |
| SCHEMBL19225380 | 0.87 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL19220536 | 0.85 | MEP1B (0.36) | GLATSHRALDH1A1MAOBRXFP1 | |
| SCHEMBL16018756 | 0.81 | IDO1 (0.39) | GLATSHRALDH1A1MAOBRXFP1 | |
| SCHEMBL18541999 | 0.81 | GLA (0.38) | GLATSHRALDH1A1MAOBRXFP1 | |
| SCHEMBL19225348 | 0.80 | ALDH1A1 (0.36) | TSHRALDH1A1P2RX7MEN1KMT2A | |
| SCHEMBL19157476 | 0.80 | GRIN2B (0.37) | ALDH1A1P2RX7MEN1KMT2ANPC1 | |
| SCHEMBL16018765 | 0.78 | MPO (0.36) | GLATSHRALDH1A1P2RX7NPC1 | |
| SCHEMBL19220571 | 0.78 | DPP4 (0.38) | GLATSHRMAOB | |
| SCHEMBL19220565 | 0.75 | MPO (0.35) | GLATSHRALDH1A1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | GLA 2034/4885TSHR 4574/4885ALDH1A1 1332/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | GLA 2034/4885TSHR 4574/4885ALDH1A1 1332/4885 |
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | GLA 2034/4885TSHR 4574/4885ALDH1A1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.